Notizie AIOM – anno XV – Pagina 15

7 Novembre 2017

ASCO Endorses ASTRO Guideline on Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma

November 3, 2017 - As reported in the Journal of Clinical Oncology by Harry Quon, MD, of Johns Hopkins University School of Medicine, and colleagues, ASCO has endorsed the recently published American Society for Radiation Oncology (ASTRO) evidence-based clinical practice ...
Leggi tutto

7 Novembre 2017

Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors: A Hoosier Cancer Research Network Study GU14-206

Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of ...
Leggi tutto

7 Novembre 2017

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Antibody-drug conjugates have emerged as a powerful strategy in cancer therapy and combine the ability of monoclonal antibodies to specifically target tumour cells with the highly potent killing activity of drugs with payloads too toxic for systemic administration. Trastuzumab ...
Leggi tutto

7 Novembre 2017

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

Randomized clinical trials have recently examined the benefit of adding docetaxel or abiraterone to androgen deprivation therapy (ADT) in hormone-naïve advanced prostate cancer (Pca). To perform a systematic review and network meta-analysis of randomized clinical trials, ...
Leggi tutto

6 Novembre 2017

3 novembre 2017 – Carenza Vaccino del Papillomavirus Umano – modalità di richiesta d’importazione dall’estero

3 Novembre 2017

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

November 1, 2017 - As reported by Catherine Van Poznak, MD, of the University of Michigan, Ann Arbor, and colleagues in the Journal of Clinical Oncology, ASCO and Cancer Care Ontario (CCO) have collaborated in providing a focused update for the ASCO clinical practice guideline ...
Leggi tutto

3 Novembre 2017

Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL

October 31, 2017 - Novartis has filed a supplemental biologics license application (sBLA) with the FDA to expand the indication for tisagenlecleucel to include adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell ...
Leggi tutto

3 Novembre 2017

FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer

November 1, 2017 - As part of the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud, the agency today issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure ...
Leggi tutto

3 Novembre 2017

FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma

November 2, 2017 - The FDA has granted GSK2857916 a breakthrough therapy designation for patients with relapsed/refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the B-cell maturation antigen (BCMA) antibody-drug conjugate. GSK2857916 is ...
Leggi tutto

3 Novembre 2017

Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC

October 30, 2017 - Merck has announced that it has withdrawn its European application for pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non–small cell lung cancer (NSCLC). A Merck spokesperson told ...
Leggi tutto

LAVORIAMO CON

News

TUMORE AL SENO: METASTASI SI DIFFONDONO COME GOCCE SU UNA SUPERFICIE. LA CAPACITÀ INVASIVA DIPENDE DALLA “FLUIDITÀ” DEL CANCRO

ONE HEALTH FOUNDATION: AL VIA IL PROGETTO IN 36 CENTRI ESTIVI IN ALBANIA. SULLA “NAVE DELLA SALUTE” SVOLTI PIU’ DI 550 TEST E VISITE MEDICHE

AL VIA LA TERZA EDIZIONE DELLA “NAVE DELLA SALUTE” ITALIA-ALBANIA. LA PREVENZIONE SALE A BORDO CON 17 MEDICI SPECIALISTI E 10 AMBULATORI

TOVORAFENIB È LA PRIMA TERAPIA MIRATA APPROVATA IN EUROPA NEL GLIOMA PEDIATRICO DI BASSO GRADO RECIDIVATO O REFRATTARIO, INDIPENDENTEMENTE DAL TIPO DI ALTERAZIONE DI BRAF

TOZORAKIMAB HA SODDISFATTO L’ENDPOINT PRIMARIO DELLO STUDIO DI FASE III MIRANDA NEI PAZIENTI CON BPCO

MIASTENIA GRAVIS, 15MILA PERSONE COLPITE IN ITALIA. “UN’INSTALLAZIONE IMMERSIVA PER COMPRENDERE LA VITA DEI PAZIENTI E AUMENTARE LA CONSAPEVOLEZZA”

MELANOMA, IN ITALIA POSSONO ESSERE “EREDITARI” 2.600 CASI L’ANNO. IMI: “LA PREVENZIONE SIA ANCHE ESAMI GENETICI E SORVEGLIANZA CUTANEA”

Notizie AIOM – anno XV

ASCO Endorses ASTRO Guideline on Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma

Phase II Trial of Pembrolizumab in Patients with Platinum Refractory Germ Cell Tumors: A Hoosier Cancer Research Network Study GU14-206

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

3 novembre 2017 – Carenza Vaccino del Papillomavirus Umano – modalità di richiesta d’importazione dall’estero

ASCO/CCO Focused Guideline Update on Role of Bone-Modifying Agents in Metastatic Breast Cancer

Novartis Submits sBLA for Tisagenlecleucel in Adults With Relapsed/Refractory DLBCL

FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer

FDA Grants BCMA Antibody-Drug Conjugate Breakthrough Status for Myeloma

Merck Withdraws EU Application for Frontline Pembrolizumab Combo in NSCLC